Nano Dimension 2022 revenue of US$43.6M, an increase of 316% over full year 2021

Sample article from our Printing & Publishing

WALTHAM, Massachusetts , March 31, 2023 (press release) –

316% Growth for Full Year 2022 Over 2021
2022 Revenue is 1,200% Higher than 2020
Q4/2022 Revenue of $12.1M is 61% Higher Than Q4/2021
and 21% Higher Than Q3/2022
  

Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printers, today announced its financial results for the fourth quarter and full year ended December 31st, 2022. 

Nano Dimension reported audited consolidated revenues of $12.1 million for the fourth quarter ended December 31st, 2022, a 61% increase over the fourth quarter of 2021 and 21% increase over the third quarter of 2022. Revenues for the full year ended December 31st, 2022, were $43.6 million, an increase of 316% over full year 2021.

CEO MESSAGE TO SHAREHOLDERS:

“We have delivered very significant revenue growth in 2022, demonstrating further progress in our strategy to drive rapid innovation that meets customer needs. We also achieved several key customer and sales milestones, including strengthening our defense customer base with orders from a European-based military force and western global aerospace and defense contractor, as well as key transactions with academic and research institutions. We also made significant strides in executing against our goal of becoming the leading AI/deep learning framework for industrial applications. The advancements we’ve made are empowering all machines in the extended Nano Dimension ecosystem through advanced industrial inspection, print quality optimization, process optimization and monitoring and maintenance of machines, a significant value-add to new and existing customers.

We hope to accelerate our organic growth in the year ahead and remain well-positioned to execute on our M&A strategy – including our recently announced offer to acquire Stratasys Ltd. (“Stratasys”), which we view as a strategic, complementary asset in the relatively mature polymer-based AM market segment – within a flexible capital deployment framework. With the intensive help of our financial advisors, Greenhill and Lazard, in addition to our ongoing exchange with Stratasys, we continue building and pursuing our pipeline of additional prospective synergistic M&A transactions.”

The Company’s organic revenue growth of previous acquisitions:

  • AM/Admatec revenue grew +60% over 6 months since acquisition.
  • Additive Electronics/Essemtec revenue grew +8% over 12 months since acquisition.
  • AM/GIS revenue grew +4% over 12 months since acquisition.

Highlights from the Financial Results for the full Years 2022 and 2021:

  • IFRS Gross Margin (“GM”) for 2022 was 32%, compared to 11% in 2021.
  • Our adjusted GM (excluding share based payments and cost of revenues from amortization of inventory and assets recognized in business combination and technology) for 2022 was 46% compared to 45% in 2021.
  • Our loss before taxes for 2022 was $228,031 thousand.
  • Our EBITDA for 2022 was $236,697 thousand.
  • Our adjusted EBITDA for 2022 was $88,804 thousand.
  • Our investment in research and development (R&D) expenses for 2022 was $75,763 thousand, which is the major part of the contributors to the negative EBITDA.
  • Our loss before taxes for 2021 was $205,730 thousand.
  • Our EBITDA for 2021 was $199,698 thousand.
  • Our adjusted EBITDA for 2021 was $43,345 thousand.
  • Our investment in R&D expenses for 2021 was $41,686 thousand, which is the major part of the contributors to the negative EBITDA.

Fourth Quarter 2022 Financial Results

  • Total revenues for the fourth quarter of 2022 were $12,104,000, compared to $9,998,000 in the third quarter of 2022, and $7,531,000 in the fourth quarter of 2021. The increase is attributed to increased sales of the Company’s product lines.
  • R&D expenses for the fourth quarter of 2022 were $20,993,000, compared to $18,535,000 in the third quarter of 2022, and $15,099,000 in the fourth quarter of 2021. The increase resulted primarily from an increase in payroll and related expenses due to more research and development resources, as well as an increase in materials expenses.
  • Sales and marketing (S&M) expenses for the fourth quarter of 2022 were $9,758,000, compared to $9,652,000 in the third quarter of 2022, and $7,690,000 in the fourth quarter of 2021. The increase compared to the fourth quarter of 2021 is resulted primarily from an increase in payroll and related expenses and marketing expenses.
  • General and administrative (G&A) expenses for the fourth quarter of 2022 were $9,091,000, compared to $7,417,000 in the third quarter of 2022, and $6,470,000 in the fourth quarter of 2021. The increase resulted primarily from an increase in payroll and related expenses as well as professional services.
  • Impairment losses for the fourth quarter of 2022 were $40,523,000. During 2022, there was a decline in the Company’s share price, such that as of December 31, 2022, the fair value of the Company, which is based on the share price, is lower than its book value of equity. Given the recoverable amount of the said cash generating units (CGUs), the goodwill, intangibles and property, plant and equipment relating to the said CGUs was reduced by approximately $40.5 million.
  • Net loss for the fourth quarter of 2022 was $87,667,000, or $0.34 per share, compared to $66,931,000, or $0.07 per share, in the third quarter of 2022, and $159,624,000, or $0.62 per share, in the fourth quarter of 2021.

Year Ended December 31st, 2022 Financial Results

  • Total revenues for the year ended December 31, 2022, were $43,633,000, compared to $10,493,000 in the year ended December 31, 2021. The increase is attributed to increased sales of the Company’s product lines.
  • Cost of revenues (excluding amortization of inventory and intangibles) for the year ended December 31, 2022, was $24,943,000, compared to $5,730,000 in the year ended December 31, 2021. The increase is attributed mostly to increased sales of the Company’s product lines.
  • R&D expenses for the year ended December 31, 2022, were $75,763,000, compared to $41,686,000 in the year ended December 31, 2021. The increase is attributed to an increase of $21,034,000 in payroll and related expenses, as well as an increase of $4,117,000 in materials and $7,480,000 in subcontractors’ expenses, due to more research and development resources, and an increase of $3,186,000 in share-based payments expenses. The increase in R&D expenses was partially offset by a decrease of $2,659,000 in depreciation.
  • S&M expenses for the year ended December 31, 2022, were $38,833,000, compared to $22,713,000 in the year ended December 31, 2021. The increase resulted primarily from an increase of $11,774,000 in payroll and related expenses, an increase of $1,004,000 in marketing, commissions and advertising expenses, as well as an increase of $1,818,000 in travel expenses and $1,185,000 in depreciation. During 2022, the Company decided to invest increased resources in sales and marketing activities, thus, it increased the number of its sales and marketing personnel.
  • G&A expenses for the year ended December 31, 2022, were $30,457,000, compared to $19,644,000 in the year ended December 31, 2021. The increase resulted primarily from an increase of $6,442,000 in payroll and related expenses and $2,709,000 in professional services due to the Company’s latest acquisitions.
  • Impairment losses for the year ended December 31, 2022, were $40,523,000.
  • Net loss for the year ended December 31, 2022, was $227,423,000, or $0.88 per share, compared to $200,777,000 or $0.81 per share, in the year ended December 31, 2021. 

Conference call information

The Company will host a conference call to discuss these financial results today, March 30th, 2023, at 9:00 a.m. EDT (4:00 p.m. IDT). We encourage participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10175112/f5aecf64c0.

Webcast link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=jXYiYYF0 .

U.S. Dial-in Number: 844-695-5517, INTERNATIONAL DIAL IN: 1-412-902-6751, Israel Dial in Number: 1-80-9212373. Please request the “Nano Dimension NNDM call” when prompted by the conference call operator. For those unable to participate in the conference call, there will be a replay available from a link on Nano Dimension’s website at http://investors.nano-di.com/eventsand-presentations

About Nano Dimension

Nano Dimension’s (Nasdaq: NNDM) vision is to transform existing electronics and mechanical manufacturing into Industry 4.0 environmentally friendly & economically efficient precision additive electronics and manufacturing – by delivering solutions that convert digital designs to electronic or mechanical devices - on demand, anytime, anywhere.

Nano Dimension’s strategy is driven by the application of deep learning based AI to drive improvements in manufacturing capabilities by using self-learning & self-improving systems, along with the management of a distributed manufacturing network via the cloud.

Nano Dimension serves over 2,000 customers across vertical target markets such as aerospace & defense, advanced automotive, high-tech industrial, specialty medical technology, R&D and academia. The company designs and makes Additive Electronics and Additive Manufacturing 3D printing machines and consumable materials. Additive Electronics are manufacturing machines that enable the design and development of High-Performance-Electronic-Devices (Hi-PED®s). Additive Manufacturing includes manufacturing solutions for production of metal, ceramic, and specialty polymers based applications - from millimeters to several centimeters in size with micron precision.

Through the integration of its portfolio of products, Nano Dimension is offering the advantages of rapid prototyping, high-mix-low-volume production, IP security, minimal environmental footprint, and design-for-manufacturing capabilities, which is all unleashed with the limitless possibilities of additive manufacturing.

For more information, please visit www.nano-di.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Nano Dimension’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Nano Dimension could differ materially from those described in or implied by the statements in this press release. For example, Nano Dimension is using forward-looking statements when it discusses its hope to accelerate its organic growth in the year ahead and remain well-positioned to execute on its M&A strategy, the Company’s offer to Stratasys and that the Company is continuing to build and pursue its pipeline of additional prospective synergistic M&A transactions. The forward-looking statements contained or implied in this press release are subject to risks and uncertainties, including those discussed under the heading “Risk Factors” in Nano Dimension’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 30, 2023, and in any subsequent filings with the SEC. Except as otherwise required by law, Nano Dimension undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Nano Dimension is not responsible for the contents of third-party websites.

NANO DIMENSION INVESTOR RELATIONS CONTACT

Investor Relations | ir@nano-di.com

Consolidated Statements of Financial Position as at

    2021     2022  
    Thousands     Thousands  
    USD     USD  
Assets            
Cash and cash equivalents     853,626       685,362  
Bank deposits     437,598       346,663  
Restricted deposits     148       60  
Trade receivables     3,422       6,342  
Other receivables     5,902       6,491  
Inventory     11,199       19,400  
Total current assets     1,311,895       1,064,318  
                 
Restricted deposits     501       850  
Bank deposits     64,371        
Investment in securities           114,984  
Deferred tax     1,007       115  
Other receivables           809  
Property plant and equipment, net     7,690       5,843  
Right of use assets     4,491       16,539  
Intangible assets            
Total non-current assets     78,060       139,140  
Total assets     1,389,955       1,203,458  
                 
Liabilities                
Trade payables     2,833       3,722  
Financial derivatives and deferred consideration     14,910       8,798  
Other payables     13,836       24,150  
Current portion of other long-term liability     417       363  
Total current liabilities     31,996       37,033  
                 
Liability in respect of government grants     1,560       1,492  
Employee benefits     4,145       1,462  
Liability in respect of warrants     3,347       69  
Lease liability     3,336       12,374  
Deferred tax liabilities     236        
Loan from banks     1,104       736  
                 
Total non-current liabilities     13,728       16,133  
Total liabilities     45,724       53,166  
                 
Equity                
Non-controlling interests     875       767  
Share capital     386,665       388,406  
Share premium and capital reserves     1,266,027       1,296,194  
Treasury shares     (1,509 )     (1,509 )
Foreign currency translation reserve     1,407       583  
Remeasurement of net defined benefit liability (IAS 19)           2,508  
Accumulated loss     (309,234 )     (536,657 )
Equity attributable to owners of the company     1,343,356       1,149,525  
Total equity     1,344,231       1,150,292  
Total liabilities and equity     1,389,955       1,203,458  

Consolidated Statements of Profit or Loss and Other Comprehensive Income
(In thousands of USD, except per share amounts)

    For the Year Ended     For the Three-Month Period Ended  
    December 31,     December 31,  
    2021     2022     2021     2022  
Revenues     10,493       43,633       7,531       12,104  
Cost of revenues     5,730       24,943       4,350       3,784  
Cost of revenues -  write-down of inventories and impairment of assets recognized in business combination and technology     3,641       4,639       2,869       649  
Total cost of revenues     9,371       29,582       7,219       4,433  
Gross profit     1,122       14,051       312       7,671  
Research and development expenses, net     41,686       75,763       15,099       20,993  
Sales and marketing expenses     22,713       38,833       7,690       9,758  
General and administrative expenses     19,644       30,457       6,470       9,091  
Impairment losses     140,290       40,523       140,290       40,523  
Operating loss     (223,211 )     (171,525 )     (169,237 )     (72,694 )
Finance income     17,909       22,965       5,326       11,105  
Finance expense     428       79,471             25,305  
Loss before taxes on income     (205,730 )     (228,031 )     (163,911 )     (86,894 )
Taxes benefit (expense)     4,906       (264 )     4,258       (1,006 )
Loss for the year     (200,824 )     (228,295 )     (159,653 )     (87,900 )
Loss attributable to non-controlling interests     (47 )     (872 )     (29 )     (233 )
Loss attributable to owners     (200,777 )     (227,423 )     (159,624 )     (87,667 )
                                 
Loss per share                                
Basic loss per share     (0.81 )     (0.88 )     (0.62 )     (0.34 )
                                 
Other comprehensive income items that after initial recognition in comprehensive income were or will be transferred to profit or loss                                
Foreign currency translation differences for foreign operations     (46 )     (844 )     (46 )     1,507  
Other comprehensive income items that will not be transferred to profit or loss                                
Remeasurement of net defined benefit liability (IAS 19), net of tax           2,508             (619 )
Total other comprehensive income (loss) for the year     (46 )     1,664       (46 )     888  
Total comprehensive loss for the year     (200,870 )     (226,631 )     (159,699 )     (87,012 )
Comprehensive loss attributable to non-controlling interests     (69 )     (892 )     (51 )     (157 )
Comprehensive loss attributable to owners of the Company     (200,801 )     (225,739 )     (159,648 )     (86,855 )

Consolidated Statements of Changes in Equity
(In thousands of USD)

    Share
capital
    Share
premium
and capital
reserves
    Remeasurement
of IAS 19
    Treasury
shares
    Presentation
/ Foreign
currency
translation
reserve
    Accumulated
loss
    Total     Non-controlling
interests
    Total
equity
 
For the year ended December 31, 2022:                                                      
Balance as of January 1, 2022     386,665       1,266,027             (1,509 )     1,407       (309,234 )     1,343,356       875       1,344,231  
Investment of non-controlling party in subsidiary     -       -       -       -       -       -             784       784  
Loss for the year     -       -       -       -       -       (227,423 )     (227,423 )     (872 )     (228,295 )
Other comprehensive loss for the year     -       -       2,508       -       (824 )     -       1,684       (20 )     1,664  
Exercise of warrants and options     1,741       (1,741 )     -       -       -       -             -        
Share based payment acquired     -       (1,005 )     -       -       -       -       (1,005 )     -       (1,005 )
Share-based payments     -       32,913       -       -       -       -       32,913       -       32,913  
Balance as of December 31, 2022     388,406       1,296,194       2,508       (1,509 )     583       (536,657 )     1,149,525       767       1,150,292  

 

    Share
capital
    Share
premium
and capital
reserves
    Remeasurement
of IAS 19
    Treasury
shares
    Presentation
/ Foreign
currency
translation
reserve
    Accumulated
loss
    Total     Non-controlling
interests
    Total
equity
 
For the three months ended December 31, 2022:                                                      
Balance as of October 1, 2022     387,646       1,291,290       3,127       (1,509 )     (848 )     (448,990 )     1,230,716       865       1,231,581  
Investment of non-controlling party in subsidiary     -       -       -       -       -       -             59       59  
Loss for the year     -       -       -       -       -       (87,667 )     (87,667 )     (233 )     (87,900 )
Other comprehensive loss for the year     -       -       (619 )     -       1,431       -       812       76       888  
Exercise of warrants and options     760       (760 )     -       -       -       -             -        
Share based payment acquired     -       (262 )     -       -       -       -       (262 )     -       (262 )
Share-based payments     -       5,926       -       -       -       -       5,926       -       5,926  
Balance as of December 31, 2022     388,406       1,296,194       2,508       (1,509 )     583       (536,657 )     1,149,525       767       1,150,292  

Consolidated Statements of Cash Flows
(In thousands of USD)

    For the Year Ended December 31,     For the three months Ended Dec 31  
    2021     2022     2021     2022  
Cash flow from operating activities:                        
Net loss     (200,824 )     (228,295 )     (159,653 )     (87,900 )
Adjustments:                                
Depreciation and amortization     7,383       7,283       2,405       1,199  
Impairment losses     140,290       40,523       140,290       40,523  
Financing (income) expenses, net     (6,873 )     (1,769 )     (5,074 )     (10,858 )
Revaluation of financial liabilities accounted at fair value     (10,608 )     (4,516 )     (252 )     335  
Revaluation of financial assets accounted at fair value           62,791             24,723  
Loss from disposal of property plant and equipment and Right of use assets     567       948       495       857  
Increase in deferred tax     (5,013 )     (581 )     (4,279 )     860  
Share-based payments     29,782       32,563       8,279       5,926  
Other           275             59  
Fees paid (*)     (70 )     (109 )     (65 )     (14 )
      155,458       137,408       141,799       63,610  
Changes in assets and liabilities:                                
(Increase) decrease in inventory     2,382       (4,603 )     2,973       (1,219 )
(Increase) in other receivables     (429 )     (1,978 )     (420 )     (5,552 )
(Increase) decrease in trade receivables     (449 )     (1,992 )     61       (231 )
Increase in other payables     1,139       5,281       1,209       3,948  
Increase in employee benefits           1,497             396  
Increase (decrease) in trade payables     74       628       (555 )     670  
      2,717       (1,167 )     3,268       (1,988 )
Net cash used in operating activities     (42,649 )     (92,054 )     (14,586 )     (26,278 )
Cash flow from investing activities:                                
Change in bank deposits, net     (416,019 )     141,555       (244,090 )     328,967  
Interest received     3,706       17,465       1,085       12,831  
Change in restricted bank deposits     (32 )     (327 )     (1 )     (311 )
Acquisition of property plant and equipment     (9,761 )     (9,388 )     (7,596 )     (3,329 )
Acquisition of subsidiaries, net of cash acquired     (74,574 )     (31,057 )     (11,930 )     1  
Payment of a liability to pay a contingent consideration of business combination           (10,708 )            
Acquisition of financial assets in fair value through profit and loss           (177,775 )            
Proceeds from sale of property plant and equipment                        
Decrease in deposit in escrow           3,362             3,362  
Other           (800 )           (800 )
Net cash used in investing activities     (496,680 )     (67,673 )     (262,532 )     340,721  
                                 
Cash flow from financing activities:                                
Proceeds from issuance of Ordinary Shares, warrants and convertible notes, net     805,497                    
Exercise of warrants and options     212             62        
Lease payments     (1,494 )     (4,151 )     (248 )     (1,063 )
Repayment long-term bank debt     (814 )     (406 )     (814 )     (103 )
Proceeds from non-controlling interests     944       510       354        
Amounts recognized in respect of government grants liability, net     (96 )     (221 )     (89 )     (89 )
Payments of share price protection recognized in business combination           (1,005 )           (261 )
Net cash provided by (used in) financing activities     804,249       (5,273 )     (735 )     (1,516 )
(Decrease) increase in cash and cash equivalents     264,920       (165,000 )     (277,853 )     312,927  
Cash and cash equivalents at beginning of the period     585,338       853,626       1,127,778       370,197  
Effect of exchange rate fluctuations on cash and cash equivalents     3,368       (3,264 )     3,701       2,238  
Cash and cash equivalents at end of year     853,626       685,362       853,626       685,362  
                                 
Non-cash transactions:                                
Property plant and equipment acquired on credit     249       52       147       (457 )
Conversion of convertible notes and warrants to equity     2,830                    
Recognition of a right-of-use asset     1,919       15,196       29       3,660  

 

  (*) reclassified

Non-IFRS measures

The following is a reconciliation of EBITDA and Adjusted EBITDA to loss before taxes, as calculated in accordance with International Financial Reporting Standards (“IFRS”):

    Year Ended
December 31,
2022
    Three-Month
Period Ended
December 31,
2022
 
(in thousands of U.S. dollars)            
Loss before taxes     (228,031 )     (86,894 )
Interest income     (18,408 )     (9,446 )
Depreciation and amortization (*)     9,742       2,125  
EBITDA (loss)     (236,697 )     (94,215 )
Exchange rate differences     16,135       (1,670 )
Finance expense for revaluation of assets and liabilities     58,672       25,304  
Share-based payments     32,563       5,926  
Impairment losses     40,523       40,523  
Adjusted EBITDA (loss)     (88,804 )     (24,132 )
                 
Gross profit (loss)     14,051       7,671  
Amortization of inventory and intangibles     4,639       649  
Share based payments     1,584       471  
Adjusted gross profit, excluding amortization of intangible assets     20,274       8,791  

 

  (*) Including amortization of assets recognized in business combination and technology.

EBITDA is a non-IFRS measure and is defined as total comprehensive loss before taxes excluding depreciation and amortization expenses and amortization of inventory and assets recognized in business combination and interest income. We believe that EBITDA, as described above, should be considered in evaluating the Company’s operations. EBITDA facilitates the Company’s performance comparisons from period to period and company to company by backing out potential differences caused by variations in capital structures, and the age and depreciation charges and amortization of fixed and intangible assets, respectively (affecting relative depreciation and amortization expense, respectively), and EBITDA is useful to an investor in evaluating our operating performance because it is widely used by investors, securities analysts and other interested parties to measure a company’s operating performance without regard to the items mentioned above.

Adjusted EBITDA is a non-IFRS measure and is defined as total comprehensive loss before taxes excluding depreciation and amortization expenses and amortization of inventory and assets recognized in business combination, interest income, finance expense for revaluation of assets and liabilities, exchange rate differences, impairment losses and share-based payments. We believe that Adjusted EBITDA, as described above, should also be considered in evaluating the Company’s operations. Like EBITDA, Adjusted EBITDA facilitates the Company’s performance comparisons from period to period and company to company by backing out potential differences caused by variations in capital structures, and the age and depreciation charges and amortization of fixed and intangible assets, respectively (affecting relative depreciation and amortization expense, respectively), as well as from revaluation of assets and liabilities, exchange rate differences, impairment losses and share-based payment expenses. Adjusted EBITDA is useful to an investor in evaluating our operating performance because it is widely used by investors, securities analysts and other interested parties to measure a company’s operating performance without regard to non-cash items, such as expenses related to revaluation, exchange rate differences and share-based payments.

Adjusted gross profit, excluding amortization of inventory and intangibles and share based payments, is a non-IFRS measure and is defined as gross profit excluding amortization expenses of inventory and intangibles and share based payment expenses. We believe that adjusted gross profit, as described above, should also be considered in evaluating the Company’s operations. Adjusted gross profit facilitates gross profit and gross margin comparisons from period to period and company to company by backing out potential differences caused by variations in amortization of inventory and intangible assets, as well as share based payments. Adjusted gross profit is useful to an investor in evaluating our performance because it enables investors, securities analysts and other interested parties to measure a company’s performance without regard to non-cash items, such as amortization expenses and share based payment expenses.

EBITDA, Adjusted EBITDA, and adjusted gross profit do not represent cash generated by operating activities in accordance with IFRS and should not be considered alternatives to net income (loss) as indicators of our operating performance or as measures of our liquidity. These measures should be considered in conjunction with net income (loss) as presented in our consolidated statements of profit or loss and other comprehensive income. Other companies may calculate these measures differently than we do.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

More from our Printing & Publishing Coverage
See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order printing & publishing coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy. We won't track your information when you visit our site. But in order to comply with your preferences, we'll have to use just one tiny cookie so that you're not asked to make this choice again.